Navigation Links
Decision Resources' Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
Date:8/17/2010

WALTHAM, Mass., Aug. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, will host the Competitive Landscape Seminar Series: Biologics and Biosimilars, a one-day seminar addressing current and future trends in the biologics and biosimilars markets on September 14, 2010. The seminar will include presentations on a range of industry and therapeutic-specific topics, and will help pharmaceutical companies understand market opportunities for biologics and biosimilars.

The seminar will be held in New York, N.Y. on September 14, 2010 and will answer the following questions:

  • Who are the key players in the biologics market and who will see the greatest growth?
  • Which companies are in the best position to produce biosimilars?
  • How quickly will biologics saturate niche markets?
  • What are the current and future prospects for biologics in the emerging markets?
  • How are payers influencing the biologics market in the United States?
  • What opportunities and challenges lie ahead for agents in specific therapeutic areas such as immune and oncology?

  • "Developments in the biologics and biosimilars markets are constantly evolving and present significant opportunities, as well as potential challenges, for pharmaceutical manufacturers," said Decision Resources Chief Operating Officer Jason LaBonte. "This high-value seminar is geared toward both manufacturers already operating in the biologics and biosimilars markets, as well as companies exploring market opportunities in this space. Attendees will leave with an understanding of the current trends in biologics and biosimilars and how these trends will shape future opportunities."

    Presentation topics include:

  • What Opportunity Remains for Emerging and Novel Immune-Targeted Agents in a TNF-Dominated World?
  • Processes and Paradigms: Which Companies Can Actually Produce Biosimilars and How?
  • Monoclonal Antibodies and the Transformation of the Oncology Landscape
  • First-Launch Small Molecule Therapies and Biologic Agents: Challenges and Opportunities Facing Novel Types of Therapies Entering New Markets
  • Moving Beyond the Major Markets: Current and Future Prospects for Biologics in the Emerging Markets

  • For more information about registration and to view the meeting agenda, please visit: http://www.competitivelandscapeseries.com/biologics-and-biosimilars/.

    Media InvitationMembers of the media interested in receiving an invitation to the Decision Resources' Competitive Landscape Seminar Series: Biologics and Biosimilars should contact Lisa Osgood at 781-296-2606 or by e-mail at losgood@hl-isy.com.

    About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

    About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

    All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision ResourcesDecision Resources, Inc.Lisa Osgood

    Christopher Comfort781-296-2606

    781-296-2597 losgood@hl-isy.com

    ccomfort@dresources.com
    '/>"/>

    SOURCE Decision Resources
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. FDA Issues Assessments of the 510(k) Program and Use of Science in Decision-Making
    2. Medco CEO to Present at the Sanford C. Bernstein & Co., LLC 26th Annual Strategic Decisions Conference 2010
    3. Abbott Chairman and CEO Miles D. White to Present at Sanford Bernstein Strategic Decisions Conference
    4. HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures
    5. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
    6. Patients, Physicians Rely on ChemoFx(R) to Support Their Cancer Treatment Decisions
    7. Kantar Health and ImpactRx Launch CancerMPact Monthly Drugs and Regimens for Oncology Business Decisions
    8. Enbrel Will Remain Decision Resources Clinical Gold Standard Through 2018 for the Treatment of Rheumatoid Arthritis
    9. Montana Supreme Court Decision Endangers Most Vulnerable Citizens
    10. Hologic Announces Decision in Patent Infringement Suit
    11. Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping Unreasonable, Unfair and Discriminatory
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/6/2016)... , Dec. 6, 2016 Diabetes & ... The diabetes and obesity disease cluster is currently dominated ... and type 2 diabetes mellitus (T2DM), and the majority ... quality of products, is attributable to these indications. While ... large market presence, there are a large number of ...
    (Date:12/6/2016)... 6, 2016 Human Vaccines Market: Scope ... wise and country wise analysis of the human ... of human vaccines products, raw material suppliers, vaccine ... the market. The report provides qualitative and ... Qualitative analysis comprises market dynamics, trends, product overview, ...
    (Date:12/6/2016)... -- BTL Aesthetics today announced the release of a ... device was effectively redesigned for more efficient, predictable ... The result: Significantly better outcomes in abdominal fat ... versus BTL Vanquish. "We are committed ... with the most highly-advanced devices on the market," ...
    Breaking Medicine Technology:
    (Date:12/7/2016)... ... December 07, 2016 , ... Gensuite ... Brilliance Awards under the Best New Product Launch category. Gensuite’s entry on their ... experience. , BOC Global Events & Training Group is a professional event and ...
    (Date:12/7/2016)... ... December 07, 2016 , ... “The Road To Restoration”: an ... not a one hour a week showing of hands. “The Road To Restoration” is ... “Perhaps you are familiar with the brass ring that you could reach out for, ...
    (Date:12/7/2016)... , ... December 07, 2016 , ... “Fred Rides a ... Christmas Day that follows. , “Fred Rides a Train” is the creation of ... short stories since her teen years in Michigan. The "Fred, the Dog" series is ...
    (Date:12/7/2016)... ... 2016 , ... Dr. Greg Leyer, the Chief Scientific Officer ... DC workshop on November 2nd. The conference was an opportunity for both probiotic ... regulations. , Dr. Leyer spoke about two main topics at the IPA ...
    (Date:12/6/2016)... ... 06, 2016 , ... People with Parkinson’s disease and cognitive ... type of MRI, according to a study appearing online in the journal Radiology. ... characterized by tremors or trembling and stiffness in the limbs, impaired balance and ...
    Breaking Medicine News(10 mins):